Loading
A phase 2 trial of Azacitidine, Venetoclax and Flumatinib in Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic myeloid leukaemia and Leukaemia, run by The First Affiliated Hospital of Soochow University, completed.
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients is a phase 2 interventional study registered as NCT05433532 by The First Affiliated Hospital of Soochow University, with 20 participants recorded, started 2022-05-01 and reaching its primary completion in 2024-04-13. Interventions recorded: Azacitidine, Venetoclax, Flumatinib. Conditions recorded: Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Mixed Phenotype Acute Leukemia.
Linked to the drug Flumatinib because the registry names it among its interventions and Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic myeloid leukaemia and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Azacitidine, Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.